|
|
rOv-ASP-1 |
|
Vaxjo ID |
189 |
|
Vaccine Adjuvant Name |
rOv-ASP-1 |
|
Adjuvant VO ID |
VO_0005327
|
|
Description |
A vaccine adjuvant that is a potent adjuvant for antibody and cellular responses to protein, polypeptide and small peptide antigens. rOv-ASP-1 stands for Recombinant Onchocerca volvulus activation-associated secreted protein-1 |
|
Stage of Development |
Research |
|
Location Licensed |
US (New York Blood Center) |
|
Host Species for Testing |
3 |
|
Components |
Recombinant Onchocerca volvulus activation-associated secreted protein-1 |
|
Preparation |
expressed as a histidine-tagged protein in E. coli (DH5α) using the pTrcHis expression vector, treated o/n with 6M urea, then purified in SDS-Page on on a PrepCell and eluted in Laemmli's buffer |
|
Function |
innate immune activation |
| References |
(Lustigman, 2023): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=43]
Jiang et al., 2014: Jiang J, Fisher EM, Hensley SE, Lustigman S, Murasko DM, Shen H. Antigen sparing and enhanced protection using a novel rOv-ASP-1 adjuvant in aqueous formulation with influenza vaccines. Vaccine. 2014; 32(23); 2696-2702. [PubMed: 24681229].
|
|
